Related Experiment Videos
A macrophage-like cell model for testing anti-CMV drugs
A S Delannoy1, D Hober, A Bouzidi
1Laboratoire de Virologie, Centre Hospitalier et Universitaire de Lille, Bâtiment IRFPPS, France.
Pathologie-Biologie
|May 1, 1997
Summary
Ganciclovir (DHPG) effectively inhibits human cytomegalovirus (HCMV) replication in differentiated THP-1 cells, a model for macrophage infection. This study highlights DHPG
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- Monocyte/macrophage cells are susceptible to human cytomegalovirus (HCMV) infection.
- These cells can serve as a reservoir and vehicle for HCMV spread.
- The THP-1 cell line, differentiated with phorbol 12-myristate 13-acetate (PMA), models macrophage infection.
Purpose of the Study:
- To investigate the efficacy of ganciclovir (DHPG) against HCMV replication in PMA-differentiated THP-1 cells.
- To determine the impact of DHPG treatment duration on HCMV replication inhibition.
- To assess the effect of DHPG pretreatment on infectious HCMV particle production.
Main Methods:
- Differentiated THP-1 cells were infected with HCMV (Towne strain).
- Cells were treated with DHPG (11.1 microM) for varying durations (2-5 days) before or after infection.
- HCMV replication was assessed by measuring viral immediate early antigens (IEA) in fibroblast cultures inoculated with cell supernatants.
Main Results:
- Incubation with DHPG for 5 days resulted in 95% inhibition of HCMV replication.
- A 2-day incubation with DHPG achieved 50% inhibition.
- Pretreatment with DHPG for 5 days reduced infectious particle production by 50%.
Conclusions:
- Ganciclovir (DHPG) demonstrates significant antiviral activity against HCMV in a macrophagic cell model.
- Treatment duration is critical for achieving maximal DHPG efficacy.
- DHPG shows potential as a therapeutic agent against HCMV in monocytes/macrophages.